IPP Bureau
Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP
By IPP Bureau - May 24, 2025
Allopurinol is used to prevent or lower high uric acid levels in the blood
Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP
By IPP Bureau - May 24, 2025
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market
By IPP Bureau - May 24, 2025
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Zydus receives final approval from USFDA for Isotretinoin Capsules USP
By IPP Bureau - May 24, 2025
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Biocon gets six-month extension on insulin supply pact in Malaysia
By IPP Bureau - May 23, 2025
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer
By IPP Bureau - May 23, 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
By IPP Bureau - May 23, 2025
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Venus Remedies secures Ukrainian GMP renewal
By IPP Bureau - May 23, 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr
By IPP Bureau - May 22, 2025
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr
By IPP Bureau - May 22, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash
By IPP Bureau - May 22, 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Neuberg Diagnostics and Star Imaging form JV for Maharashtra’s largest integrated diagnostics network
By IPP Bureau - May 22, 2025
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio
By IPP Bureau - May 21, 2025
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
By IPP Bureau - May 21, 2025
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Venus Remedies joins United Nations Global Compact
By IPP Bureau - May 21, 2025
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
